Arch Biopartners receives patent for Metablok

Is the first patent issued protecting the composition and method of use for Metablok, the company's drug candidate targeting inflammation, sepsis and cancer metastasis.

This is the first patent issued protecting the composition and method of use for Metablok, the Company's drug candidate targeting inflammation, sepsis and cancer metastasis.

"This patent establishes Metablok as a leading commercial opportunity in the Arch portfolio and provides a clear path for human clinical trials" said Dr. Daniel Muruve, Chief Science Officer of Arch and Professor of Medicine at the University of Calgary.

Management of Arch believes Metablok has the potential to be a major breakthrough in the treatment of diseases where inflammation plays a major role, as well as in sepsis and cancer metastasis. Arch is currently pursuing further clinical development of Metablok and expects to make additional disclosures as milestones toward a human trial are completed over the next few months.

This patent is based on technology invented by Dr. Stephen Robbins, Dr. Donna Senger, Dr. Paul Kubes and Dr. Jennifer Rahn at the University of Calgary who previously assigned the intellectual property of Metablok to Arch.